Information  X 
Enter a valid email address

Novacyt S.A. (NCYT)


Tuesday 12 April, 2022

Novacyt S.A.

Approval of COVID-19 test under CTDA legislation

RNS Number : 0373I
Novacyt S.A.
12 April 2022

Novacyt S.A.

("Novacyt", the "Company" or the "Group")


Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation


Paris, France and Camberley, UK - 12 April 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's PROmate ®   COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA").


The PROmate® COVID-19 1G test for use on Novacyt's q32 instrument is the Company's second direct-to-PCR and third product to be added to the CTDA register of approved products. The test is designed to detect a SARS-CoV-2 gene target within ORF1ab and, as with all the Company's direct-to-PCR products, removes the need for complex, manual, or automated extraction solutions to significantly improve laboratory workflow and reduce costs. The test was previously on the CTDA Temporary Protocol list of products which can continue to be sold in the UK whilst validation is being processed.


As previously announced, Novacyt's PROmate® COVID-19 1G test for use on the Company's q16 instrument (currently on the Temporary Protocol list) continues to be   supplied to the NHS under a National Microbiology Framework.


Please see below the status of the 11 products Novacyt submitted to the CTDA before the deadline of 1 September 2021. The Company awaits further updates on the products submitted to the CTDA across its COVID-19 testing portfolio.



Product name

Current CTDA status


genesig® COVID-19 Real-Time PCR

Approved November 2021


PROmate® COVID-19 2G

Approved February 2022


PROmate ® COVID-19 1G (q32)

Approved April 2022


PROmate ® COVID-19 1G (q16)

On Temporary Protocol*


genesig® COVID-19 3G Real-Time PCR

Evaluation in progress


genesig® Real-time PCR SARS-CoV-2 Winterplex


exsig™ COVID-19 direct


SARS-CoV-2 Antigen Rapid


genesig® COVID-19 3G HT



genesig® Real-Time PCR COVID-19 HT

genesig® COVID-19 2G Real-Time PCR

Withdrawn **

* Temporary Protocol list due to expire on 31 May 2022.

** Following feedback from the UK HSA and significantly diminished market demand for these particular products, the Company has decided not to pursue approval any further. Demand for these products can be substituted with other products in the Company's portfolio.


David Allmond, Group CEO of Novacyt, commented:

" Our PROmate® COVID-19 range remains at the forefront of COVID-19 testing for busy laboratories and clinicians requiring workflow efficiency, combined with exceptional clinical performance. Providing total viral inactivation without the need for a category 2 laboratory to handle the live virus, our PROmate® tests reduce handling risk and help bring testing nearer to patients. We look forward to continuing to meet the demand for high quality COVID-19 testing in the UK, as well as leveraging our direct-to-PCR technology for new disease targets in future."


- End -



Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470


Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000


Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[email protected] / [email protected]


FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[email protected] / [email protected] / [email protected]  


FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[email protected]  


About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.


For more information, please refer to the website:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t